Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT06279247
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
5 Years - 100 Years
Healthy Volunteers
Accepted

Study Details

Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed. At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.

Key Dates

Start date
Sep 1, 2022
Status verified
Dec 2025
Primary completion
Aug 26, 2026
Completion
Aug 26, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: narcolepsy group
  • Arm: health control group

Primary Outcome Measure

To screen potential molecular markers related to the biological characteristics and prognosis of narcolepsy. [ Time Frame: 2022.09~2024.09 ]

Central Contacts

Related Studies